Under the FDA Modernization Act of 1997, shows Fast Track designation, the FDA can facilitate the development the review the review of a drug if was the treatment of a serious or life-threatening condition and demonstrates the potential to address a unmet medical needs for such a condition levitra bayer .

Lexiva is a registered trademark of the GlaxoSmithKline group of companies.Vertex press releases can be found atVertex Pharmaceuticals IncorporatedVertex Pharmaceuticals Incorporated today announced that it has initiated a Phase I clinical trial of VX-770, a novel oral drug candidate, which specifically a key mechanism underlying cystic fibrosis . The study and the safety, tolerability and pharmacokinetics of escalating single and multiple doses of VX-770 in healthy subjects will also assess single doses of VX-770 in patients with CF. The trial is expected to take more than 50 persons. In March 2006, Vertex and Cystic Fibrosis Foundation Therapeutics Inc. entered into a cooperative clinical development of VX-770 to accelerate. CFFT is the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation. Vertex retains worldwide rights to develop and commercialize VX-770. – ‘This first clinical study of VX-770 is an important milestone in the history the productive relationship that Vertex Vertex in the discovery of new CF therapies is,’said Robert J. President and Chief Executive Officer of the Cystic Fibrosis Foundation and CFFT. ‘We believe that compounds such as VX-770 have great potential to change the course of CF, and we are pleased to support the accelerated development of VX-770 in early clinical trials. ‘ – ‘With VX-770 the first drug candidate arising from our innovative CF research efforts, and the initiation of the Phase I study represents an exciting new phase in the development of this compound,’said John Alam, Executive Vice President, Medicines Development and Chief Medical Officer for Vertex. ‘Laboratory results for VX-770 have been extremely encouraging and support the initiation of this first clinical trial. We look forward to evaluating VX-770 in healthy subjects and patients with CF in the coming months to determine next steps for the determination VX-770 development program. ‘.

köp på nätet

It Kashmir earthquake available different lessons, especially as regards the risk of acute renal failure . This is of special concern break down earthquakes or other causes of building By Robert J. Able damages damage by pinches a condition known rhabdomyolysis, which can quickly lead to ARF.